Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
Clinical trial NCT05864742 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05864742
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-07
- Primary completion
- 2026-06-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.